fashion -WSS

fashion

author：focus 2025-08-12 08:30:07 - browse：2

Drug shortages are a growing problem in the U.S., and a shortage of livesaving cancer drugs in particular has reached crisis levels.

On the latest episode of the “First Opinion Podcast,” oncologist Kristen Rice explains that drug shortages have been happening for several years but have been progressively worsening in the past few months. Oncologists are facing critical shortages of common, generic cancer medications and have even begun to ration care for certain patients who are able to delay treatment, according to Rice.

“Patients are already under a lot of stress — they’re dealing with a cancer diagnosis, and they’re terrified. The last thing they want to hear is that something that’s critical to controlling their cancer might not be available, and we’re wondering where the next dose is going to come from,” Rice said.

The conversation is based off Rice’s recent First Opinion, “Cancer drug shortages should have patients rioting in the streets.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Childhood cancer progress stalls for Black, Hispanic kids: Report

explore

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

FDA proposes changes to key medical devices approval pathway

Weight loss drug costs may need more research, senator suggests

Generate Biomedicines machine learning biotech raises $273M

FDA's Woodcock to retire early next year

Food makers to regulators: Ultra

leisure time

fashion

leisure time

Sports medicine is finally prioritizing gender equality

Congress must reauthorize a committee to support older Americans

ChatGPT in medicine: STAT answers readers' burning questions

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Peter Hotez and the public health issue of online harassment

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Duchenne breakthrough therapy leaves behind pioneering families

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Jerome Adams on the need for new antivirals for Covid

David Sabatini, ex

explore

Regeneron agrees to White House price limits on anti

Hospitals look to new technology to keep health care workers safe

Surge of respiratory disease in China has likely explanation

Morphosys mixed study results for blood cancer drug

IRA could hurt research into orphan drugs for rare diseases

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

explore

knowledge

entertainment

hotspot